Visit newsbetting.cv for more information.
Interim Data From Two Ongoing Investigator-initiated Trials Highlight the Role of Sculptra® and Restylane® in Addressing Aesthetic Changes Associated With Weight Loss Medications and Menopause
· Financial Post
ZUG, Switzerland -- Galderma (SIX: GALD), the pure-play dermatology category leader, today welcomes new data from two IITs, demonstrating the power of Sculptra – the first proven regenerative biostimulator – and the company’s versatile hyaluronic acid injectable Restylane range, in addressing the aesthetic changes associated with menopause and medication-driven weight loss, for the face and body.1-7 Data includes an analysis from a first-of-its-kind study evaluating optimal treatment sequencing to enhance women’s skin during menopause, and an evaluation of the cellular makeup of fat in the abdomen following medication-driven weight loss.1,2 Read More